LOCALLY ADVANCED UROTHELIAL CARCINOMA

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This study tests whether pembrolizumab, an immunotherapy drug that helps the immune system fight cancer, can prevent bladder or urinary tract cancer from returning after surgery. About 739 people with muscle-invasive or locally advanced urothelial cancer took part. The drug is gi…

This early-stage trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest and most effective dose and see if the combo can shrink or stab…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This study tests a new combination of drugs (MK-2870 plus enfortumab vedotin, with or without pembrolizumab) in people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 38 adults will take part in two phases: fir…

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with cancer that has spread will receive the drug alone or with pembrolizumab. The goal is to see if a de-escalated schedu…

This early-stage trial was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer that had not been treated before. The goal was to see if the combination was safe and could help control the cancer. Howe…

This early-phase trial is testing a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus a targeted drug (belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understa…

This early-phase study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. Tazemetostat blocks certain enzymes that help cancer grow, while pembrolizumab helps the immune system fight the cancer. The goal is to f…

This study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…

This study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…